Havena Harahn on Muck Rack

Havena Harahn

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Havena

Contact Havena, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration

|
By Imran Janmohamed, Hasan Ahmed, Luke Membrey, Havena Harahn, Barnaby Carr, Saleh Sahbi, Abdelrahman Farahat, Shabeeba Hannan
| Nature Verified
Abstract Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg. This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified